Key facts
- This page summarizes Harry L. Leider's Form 4 filing for Organicell Regenerative Medicine, Inc. (ZEOX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 Dec 2023, 16:05.
Harry L. Leider - 19 Dec 2023 Form 4 Insider Report for Organicell Regenerative Medicine, Inc. (ZEOX)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- ZEOX
- Reported as of
- 19 Dec 2023
- Net transaction value
- -$6,901
- SEC form
- 4
- Accepted by SEC
- 20 Dec 2023, 16:05:26 UTC
- Prior SEC filing
- 30 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Harry L. Leider
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Harry L. Leider filed Form 4 for Organicell Regenerative Medicine, Inc. (ZEOX) on 20 Dec 2023.
Change
- Previous filing in this sequence was filed on 30 Jun 2023.
- Current net transaction value: -$6,901.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OCEL
transaction
Common Stock
Sale
- Transaction value
- $6,901
- Shares
- -5,248
- Change %
- -100%
- Price
- $1.32
- Shares after
- 0
- Date
- 19 Dec 2023
- Ownership
- See footnote
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares disposed of were held by the Harry L. Leider Revocable Trust of which the Reporting Person is the Trustee.